InVitro International Progresses with Growth Strategies and Continues Profitability
InVitro International (OTCQB: IVRO) reported its Q3 FY '24 financial results, showing a 16% decrease in sales to $167,850 compared to the same quarter last year. However, the company achieved a net income of $16,236, a significant improvement from the $13,162 loss in Q3 FY'23. For the first three quarters of FY'24, sales totaled $590,090, down 3% from FY'23, but year-to-date earnings surged to $81,582, a 272% increase from the prior year's losses. CEO W. Richard Ulmer highlighted the company's focus on maintaining profitability for the 19th consecutive year and pursuing growth through M&A financing and qualifying private laboratories. Ulmer also emphasized the promising future of non-animal testing in the industry.
InVitro International (OTCQB: IVRO) ha riportato i risultati finanziari del terzo trimestre dell'anno fiscale '24, evidenziando una diminuzione del 16% nelle vendite, scese a 167.850 dollari rispetto allo stesso trimestre dell'anno precedente. Tuttavia, l'azienda ha registrato un utile netto di 16.236 dollari, un notevole miglioramento rispetto alla perdita di 13.162 dollari nel terzo trimestre dell'anno fiscale '23. Per i primi tre trimestri dell'anno fiscale '24, le vendite hanno totalizzato 590.090 dollari, in calo del 3% rispetto all'anno fiscale '23, ma i guadagni dell'anno fino ad oggi sono saliti a 81.582 dollari, un incremento del 272% rispetto alle perdite dell'anno precedente. Il CEO W. Richard Ulmer ha sottolineato l'impegno dell'azienda nel mantenere la redditivit脿 per il 19掳 anno consecutivo e nel perseguire la crescita attraverso finanziamenti M&A e la qualificazione di laboratori privati. Ulmer ha anche evidenziato il futuro promettente dei test su non animali nel settore.
InVitro International (OTCQB: IVRO) inform贸 sus resultados financieros del tercer trimestre del a帽o fiscal '24, mostrando una disminuci贸n del 16% en las ventas, que alcanzaron $167,850 en comparaci贸n con el mismo trimestre del a帽o pasado. Sin embargo, la compa帽铆a logr贸 un ingreso neto de $16,236, una mejora significativa respecto a la p茅rdida de $13,162 en el tercer trimestre del a帽o fiscal '23. En los primeros tres trimestres del a帽o fiscal '24, las ventas totalizaron $590,090, una ca铆da del 3% en comparaci贸n con el a帽o fiscal '23, pero las ganancias acumuladas hasta la fecha alcanzaron los $81,582, un aumento del 272% con respecto a las p茅rdidas del a帽o anterior. El CEO W. Richard Ulmer destac贸 el enfoque de la empresa en mantener la rentabilidad durante el 19掳 a帽o consecutivo y en buscar crecimiento mediante financiamiento de M&A y la calificaci贸n de laboratorios privados. Ulmer tambi茅n enfatiz贸 el futuro prometedor de las pruebas sin animales en la industria.
InVitro International (OTCQB: IVRO)臧� 2024 須岅硠 鞐半弰 3攵勱赴 鞛 瓴瓣臣毳� 氚滍憸頄堨溂氅�, 毵れ稖鞚� 16% 臧愳唽頃橃棳 $167,850鞐� 鞚措ゴ霠�鞀惦媹雼�. 鞚措姅 歆�雮滍暣 臧欖潃 攵勱赴鞕� 牍勱祼霅� 靾橃箻鞛呺媹雼�. 攴鸽煬雮� 須岇偓電� 靾滌澊鞚� 16,236雼煬毳� 雼劚頄堨溂氅�, 鞚措姅 2023 須岅硠 鞐半弰 3攵勱赴鞐愳劀 13,162雼煬鞚� 靻愳嫟鞐� 牍勴暣 靸侂嫻頃� 臧滌劆鞚� 雮橅儉雰呺媹雼�. 2024 須岅硠 鞐半弰 觳� 靹� 攵勱赴 霃欖晥 毵れ稖鞚� 齑� $590,090搿�, 2023 須岅硠 鞐半弰 雽�牍� 3% 臧愳唽頄堨溂雮�, 鞓暣 雸勳爜 鞚挫澋鞚� $81,582搿�, 歆�雮滍暣 靻愳嫟 雽�牍� 272% 歃濌皜頄堨姷雼堧嫟. CEO W. Richard Ulmer電� 須岇偓臧� 19雲� 鞐办啀鞙茧 靾橃澋靹膘潉 鞙犾頃橁碃, 鞚胳垬頃╇硲(M&A) 鞛愱笀鞚� 韱淀暅 靹膘灔 於旉惮 氚� 氙缄皠 鞁ろ棙鞁� 鞚胳鞐� 齑堨爯鞚� 毵烄稊瓿� 鞛堨潓鞚� 臧曥“頄堨姷雼堧嫟. Ulmer電� 霕愴暅 靷办梾 雮� 牍勲彊氍� 韰岇姢韸胳潣 鞙犽頃� 氙鸽灅毳� 臧曥“頄堨姷雼堧嫟.
InVitro International (OTCQB: IVRO) a annonc茅 ses r茅sultats financiers du troisi猫me trimestre de l'exercice '24, affichant une baisse de 16% des ventes, qui se sont 茅lev茅es 脿 167.850 dollars par rapport au m锚me trimestre de l'ann茅e derni猫re. Toutefois, l'entreprise a r茅alis茅 un b茅n茅fice net de 16.236 dollars, une am茅lioration significative par rapport 脿 la perte de 13.162 dollars au troisi猫me trimestre de l'exercice '23. Pour les trois premiers trimestres de l'exercice '24, les ventes ont totalis茅 590.090 dollars, en baisse de 3% par rapport 脿 l'exercice '23, mais les b茅n茅fices 脿 date ont bondi 脿 81.582 dollars, un augment de 272% par rapport aux pertes de l'ann茅e pr茅c茅dente. Le PDG W. Richard Ulmer a soulign茅 l'engagement de l'entreprise 脿 maintenir la rentabilit茅 pour la 19e ann茅e cons茅cutive et 脿 rechercher la croissance par le biais de financements M&A et de la qualification de laboratoires priv茅s. Ulmer a 茅galement insist茅 sur l'avenir prometteur des tests sans animaux dans le secteur.
InVitro International (OTCQB: IVRO) berichtete 眉ber die finanziellen Ergebnisse des dritten Quartals des Gesch盲ftsjahres '24 und verzeichnete einen R眉ckgang des Umsatzes um 16% auf 167.850 US-Dollar im Vergleich zum gleichen Quartal des Vorjahres. Das Unternehmen erzielte jedoch einen Nettoeinkommen von 16.236 US-Dollar, was eine erhebliche Verbesserung im Vergleich zu dem Verlust von 13.162 US-Dollar im dritten Quartal des Gesch盲ftsjahres '23 darstellt. In den ersten drei Quartalen des Gesch盲ftsjahres '24 belief sich der Umsatz auf insgesamt 590.090 US-Dollar, ein R眉ckgang von 3% gegen眉ber dem Gesch盲ftsjahr '23, w盲hrend die Ertr盲ge bis zum heutigen Datum auf 81.582 US-Dollar anstiegen, ein Zuwachs von 272% im Vergleich zu den Verlusten des Vorjahres. CEO W. Richard Ulmer hob den Fokus des Unternehmens hervor, die Rentabilit盲t im 19. Jahr in Folge aufrechtzuerhalten und Wachstum durch M&A-Finanzierung und die Qualifizierung privater Labore zu verfolgen. Ulmer betonte auch die vielversprechende Zukunft der tierversuchsfreien Tests in der Branche.
- Net income of $16,236 in Q3 FY'24, compared to a loss of $13,162 in Q3 FY'23
- Year-to-date earnings of $81,582, a 272% increase from prior year losses
- 19 consecutive years of profitability maintained
- Progress in seeking M&A financing and qualifying private laboratories for growth
- Q3 FY'24 sales decreased by 16% to $167,850 compared to the same quarter last year
- Three quarters FY'24 sales of $590,090 were 3% lower than FY'23's total of $608,195
Placentia, California--(Newsfile Corp. - July 31, 2024) - Today, InVitro International (OTCQB: IVRO) announced third quarter FY '24 sales of
IVRO CEO W. Richard Ulmer stated: "Our FY '24 focus has been on continuing 19 consecutive years of profitability, in addition to concentrating efforts on growth via two previously stated strategies. We're pleased with our progress seeking M&A financing, and also qualifying privately owned candidate laboratories. The future for NON-Animal testing remains bright."
Company Contact:
W. Richard Ulmer
Chief Executive Officer and Chairman
(800) 246-8487
[email protected]
To view the source version of this press release, please visit
FAQ
What were InVitro International's (IVRO) Q3 FY'24 financial results?
How did InVitro International's (IVRO) year-to-date earnings perform in FY'24?
What growth strategies is InVitro International (IVRO) pursuing?
How many consecutive years of profitability has InVitro International (IVRO) maintained?
